Feature Drugs for Neglected Diseases US incentive scheme for neglected diseases: a good idea gone wrong? BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g4665 (Published 21 July 2014) Cite this as: BMJ 2014;349:g4665 Article Related content Metrics Responses Peer review Related articles No related articles found. See more US women must be told breast density after mammogram, says FDA BMJ September 18, 2024, 386 q2045; DOI: https://doi.org/10.1136/bmj.q2045 Semaglutide’s CVD indication could cost US Medicare $145bn extra a year BMJ August 28, 2024, 386 q1878; DOI: https://doi.org/10.1136/bmj.q1878 Microdosing mushroom sweet treats are recalled in US after six hospital admissions and two potential deaths BMJ August 27, 2024, 386 q1871; DOI: https://doi.org/10.1136/bmj.q1871 Over-the-counter painkillers may not be sufficient when fitting IUDs, says US agency BMJ August 19, 2024, 386 q1820; DOI: https://doi.org/10.1136/bmj.q1820 Michael Bloomberg donates $600m to historically black US medical schools BMJ August 08, 2024, 386 q1766; DOI: https://doi.org/10.1136/bmj.q1766 Cited by... European priority review vouchers for neglected disease product developmentAbstract Fulltext PDF Chagas Disease in the United States: a Public Health ApproachAbstract Fulltext PDF Why miltefosine--a life-saving drug for leishmaniasis--is unavailable to people who need it the mostAbstract Fulltext PDF Repairing The Broken Market For Antibiotic InnovationAbstract Fulltext PDF Legislation governing the US incentive scheme for neglected diseases needs to be amended, urges MSFAbstract Fulltext PDF
